Noventure Signs Exclusive Agreement with Global Partner Azur

By CIOReview | Wednesday, February 24, 2021

FREMONT, CA: Noventure, a Spanish company specialized in licensing innovative substance-based medical devices and specialist food supplements announced that it has reached an exclusivity agreement with global partner Azur, a subsidiary of Solutexx, to license the groundbreaking food supplement EPA3G.

There is a large abundance of omega-3 supplements in the industry. There is a lot of discussion about the amount of omega-3 needed to have substantial health benefits and a realistic dose to meet regular lifestyles. The new multi-serving choices, or those bulky, hard-to-swallow capsules, are not ideal.

“Noventures mission is to shape innovative science assets and bring them to markets around the world. With this agreement, people will now have a differentiated, value-added omega-3 product, which is effective and easy to use,” said Luciano Conde, CEO, Noventure. “We are very pleased to work with Azur, together we will keep building strong partnerships based on a shared understanding of user’s needs and pursue market opportunities whilst growing together.”

EPA3G effectively fills this market gap. EPA3G is a patented, state-of-the-art drinkable emulsion sold in sachets, with exceptional texture, flavor, and fragrance, with nearly three grams of pure EPA (eicosapentaenoic acid) in one easy-to-take everyday dosage. Noventure has the right to license EPA3G to specialist firms under the terms of the deal. They must have marketing experience and skills in the marketing of high-end nutritional supplements. The deal includes more than 50 countries on numerous continents, including EU and Affiliate Member Nations, the United Kingdom, the Balkans, Russia, Ukraine, Eurasia, Mexico, Taiwan, and some African States.

“Globally, EPA is gaining importance and becoming a part of many consumers' daily diet. The key reasons for this market growth have been the increased prevalence of lifestyle diseases and people choosing preventive healthcare measures,” said Julio Boza, CEO, Azur. Consumer desire for high effectiveness and bioavailability has also ensured manufacturers seek more highly concentrated forms to provide EPA efficacious doses better. We are delighted to work with Noventure. We believe this technology will allow people to satisfy their omega-3 requirements in a convenient drinkable format. This is an excellent example of transforming bright science and technology into breakthrough, sustainable commercial solutions and is an example of how to work and grow together.”